Appointed
Christopher A. Marlett
Chairman of the Board
EXOZ ·
EXOZYMES INC.
The Board also appointed Mr. Christopher A. Marlett as the Chairman of the Board on the same date.
Ready 8-Ks
17
Latest filing
June 8, 2026, 2:19 PM ET
Top materiality
0.75
Event mix
other_material ×13 · other ×2 · leadership ×2
Sentiment
4 pos · 0 neg · 13 neu
Executive change
recent →
Recent 8-K filings for EXOZ
Highest-materiality recent filing
Invizyne completes $15M IPO; shares begin trading on Nasdaq under IZTC
- Priced 1,875,000 shares at $8.00; gross proceeds $15M, net proceeds ~$14.3M.
- Concurrent private placement issued 93,750 warrants at $0.125, exercisable at $8.00 for 5 years.
-
eXoZymes prices $5.33M offering of common stock and warrants at $18/unit
Sold 592,270 shares and 296,135 warrants as units at $18.00; gross proceeds ~$5.33M.
-
eXoZymes reports 535g NCT pilot run at 99% conversion, 90% yield, 99.6% purity
Achieved ~99% reaction conversion, 90% isolated yield, and 535 g of NCT at 99.6% pharma-grade purity from a 100L pilot run.
-
eXoZymes to receive $3M from NSF as key partner in $9.2M cell-free biomanufacturing initiative
Selected as core industrial partner in Meta-PURE, a $9.2M NSF-funded project under CFIRE program.
-
Invizyne completes $15M IPO; shares begin trading on Nasdaq under IZTC
Priced 1,875,000 shares at $8.00; gross proceeds $15M, net proceeds ~$14.3M.
Executive changes
Departed
Mohammad Hayat
President and Chairman
EXOZ ·
EXOZYMES INC.
On February 17, 2025, Mr. Mohammad Hayat, a member of the Board of Directors (the “ Board ”) of eXoZymes Inc., a Nevada corporation (the “ Company ”), as well as its President and Chairman of the Board, resigned from the Board and from all positions he held in the Company.
Appointed
Edgardo Rayo
member of the Board
EXOZ ·
EXOZYMES INC.
On February 17, 2025, the Board appointed Mr. Edgardo Rayo as a member of the Board to fill the vacancy created by Mr. Hayat’s resignation.
Materiality & sentiment trend
Max materiality 0.75 · Median 0.50 · Most common event other_material